Opinion
Video
Author(s):
Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
Subcutaneous nivolumab under review in EU for solid tumors
FDA approves durvalumab/chemo for muscle–invasive bladder cancer
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC